Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: TKI alone: Various TKI at recommended standard doses (for eg. Gefitinib - 250 mg OD and Erlotinib - 100 mg PO OD)
Control Intervention1: Cranial RT and TKI: Cranial RT doses like SRS -2
Sponsors
Anil Tibdewal
Eligibility
Inclusion criteria
Inclusion criteria: Age >= 18 years Patients with ECOG performance status of 0-2 Patients with pathologically proven diagnosis of NSCLC Patients with positive oncogene mutation status (EGFR/ALK) Patients with radiologically confirmed parenchymal brain metastases Patients with asymptomatic Synchronous or Metachronous brain metastases Patients willing for written informed consent and must be willing to comply with the specified follow up schedule
Exclusion criteria
Exclusion criteria: Patients with CSF dissemination only without any parenchymal brain metastases Patients with brain metastases in the brain stem Patients with prior history of radiation therapy to brain Patient not suitable for TKI therapy as per the medical oncologist Preganant or Lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intracranial progression free survival between the two armsTimepoint: Two year | — |
Secondary
| Measure | Time frame |
|---|---|
| NeurocognitionTimepoint: baseline, 3, 6 and 12 months;Objective response rateTimepoint: Not Applicable;Overall survivalTimepoint: Two year;Progression free survivalTimepoint: Two Year;Treatment related toxicityTimepoint: at 3, 6 and 12 months | — |
Countries
India
Contacts
Public ContactAnil Tibdewal
Tata Memorial Hospital
Outcome results
None listed